N/A (Standalone) Deal Activity — 17 Deals Analyzed

17 Deals in 18 Months: N/A (Standalone)'s Aggressive Dealmaking Pace

N/A (standalone) closed 17 deals between July 2022 and January 2024 — a pace of roughly one deal per month across 10 distinct therapeutic areas. That breadth alone sets this entity apart. While most mid-to-large pharma players cluster their BD activity around two or three core TAs, N/A (standalone) has been deploying capital across dermatology, hematology, gastroenterology, infectious disease, ophthalmology, rare disease, oncology, women's health, cardiovascular, and immunology. The heaviest concentration sits in dermatology (four deals, including three approved-stage psoriasis assets with total deal values of $2.8B, $4.2B, and $8.2B respectively) and infectious disease (two approved-stage deals totaling $8.2B in combined TDV). This is not a company fishing in early-stage waters — it is buying revenue-stage or late-stage clinical assets at premium valuations.

N/A (Standalone)'s Deal Portfolio

The pattern is unmistakable: N/A (standalone) is concentrating firepower in dermatology — specifically psoriasis — while simultaneously building positions across high-value specialty markets. Four of the ten visible deals target dermatology, with three psoriasis assets alone carrying a combined TDV north of $15B. That is not diversification for its own sake. That is a deliberate franchise play in inflammatory skin disease.

Beyond dermatology, the portfolio reveals selective bets in markets with strong pricing power: rare disease (ATTR at $5.5B TDV), gastroenterology (Crohn's at $7.1B TDV), and infectious disease (HIV/AIDS and RSV combining for $8.2B TDV). The ophthalmology deal — diabetic macular edema at Phase 2 with a $300M TDV — is the only genuinely early-stage, lower-value bet in the visible portfolio. Everything else screams late-stage conviction buying.

Deal Type Preferences

N/A (standalone)'s preferred deal structures are licenses and collaborations. No acquisitions. No option deals. No equity-based structures. This tells you three things about their risk calculus.

First, they want optionality without full ownership. Licensing and collaboration structures let them access commercial-stage or near-commercial assets while sharing downside with the originator. Given the TDV scale of these deals — seven of ten visible transactions exceed $2B — the milestone-heavy structure inherent in licensing frameworks provides natural hedging against underperformance.

Second, they are building a portfolio, not integrating companies. This is a critical distinction. Acquirers absorb teams, infrastructure, and overhead. Licensees absorb assets. N/A (standalone) is running a lean, asset-centric model that avoids the integration tax of M&A.

Third, they are comfortable paying large total deal values. The absence of disclosed upfront payments across all ten visible deals makes it impossible to benchmark their upfront-to-TDV ratios against industry norms. But TDV figures ranging from $300M to $8.2B indicate willingness to structure significant milestone packages. For any biotech negotiating with N/A (standalone), expect the conversation to center on milestone architecture — not just the upfront check. Use the Deal Calculator to benchmark where your terms should land relative to comparable transactions in your TA.

Strategic Pattern

Three strategic threads connect N/A (standalone)'s deal activity from 2022 to 2024.

1. Dermatology Franchise Consolidation

Three separate psoriasis deals — all for approved assets — with TDVs of $2.8B, $4.2B, and $8.2B. Add the vitiligo deal at $500M. N/A (standalone) is building (or has built) one of the most concentrated dermatology portfolios in the industry through licensing alone. This is a franchise strategy: control multiple approved assets in the same indication to capture market share across patient segments, payer negotiations, and geographic territories. Anyone working in dermatology should study these deal structures closely.

2. Late-Stage Conviction Buying Across Specialty Markets

Eight of ten visible deals target approved or Phase 3 assets. The two Phase 2 exceptions — polycythemia vera ($2B TDV) and diabetic macular edema ($300M TDV) — are both in areas with clear clinical endpoints and well-understood regulatory paths. N/A (standalone) is not taking early discovery risk. They are paying up for de-risked assets where the remaining uncertainty is commercial, not clinical.

3. Therapeutic Breadth as Strategic Insurance

Ten TAs across 17 deals is unusual. Most dealmakers with this volume concentrate in three to four areas. N/A (standalone)'s breadth — from cardiovascular to women's health to immunology — suggests one of two things: either this entity is acting as a holding structure for multiple operating units with distinct TA mandates, or it is deliberately building a diversified specialty portfolio to insulate against single-indication revenue concentration risk. Either way, the signal to biotechs is clear: N/A (standalone) will look at assets across the therapeutic spectrum, provided they meet the stage and commercial readiness bar.

What This Means If You're Pitching to N/A (Standalone)

If you are a biotech considering N/A (standalone) as a licensing or collaboration partner, here is what the data tells you about how to position your asset.

• Stage matters more than novelty. N/A (standalone) overwhelmingly favors approved or Phase 3 assets. If you are pre-Phase 2, you are likely too early for their appetite — unless your indication has an exceptionally clean regulatory path and you can demonstrate accelerated timelines to de-risk. The $300M DME deal at Phase 2 is the exception, not the rule.
• Dermatology and infectious disease are the sweet spots. Six of ten visible deals fall into these two TAs. If your asset is in psoriasis, atopic dermatitis, vitiligo, HIV, RSV, or adjacent indications, you are pitching into demonstrated demand. Come prepared with head-to-head positioning data against the assets they have already licensed.
• Propose a licensing structure, not a co-development framework. N/A (standalone)'s deal type preferences are clear: license and collaboration. Do not pitch an acquisition or option deal. Structure your term sheet around milestones — regulatory, commercial, and sales-based — with a defensible TDV narrative. They have shown willingness to sign deals with TDVs exceeding $5B for the right asset.
• Expect pushback on upfront payments. The absence of disclosed upfronts across all visible deals is notable. While this may reflect data availability rather than actual deal terms, it raises a reasonable hypothesis: N/A (standalone) may prefer milestone-weighted structures that limit upfront cash exposure. If you need significant upfront capital, prepare a strong justification tied to asset maturity and competitive dynamics.
• Benchmark aggressively. With TDVs ranging from $300M to $8.2B, N/A (standalone) is accustomed to large-scale transactions. Do not underprice your asset. Use Partner Matching to see how N/A (standalone) compares against 850+ other potential partners for your specific asset profile, and come to the table with tier-appropriate expectations.

See Which Companies Match Your Asset

N/A (standalone) is one of hundreds of active dealmakers in biopharma licensing. Whether your asset fits their profile or aligns better with another buyer, the Ambrosia calculator's partner matching engine scores 850+ companies against your asset's therapeutic area, stage, modality, and deal structure preferences. Run your match now — it takes under two minutes and gives you a ranked list of the buyers most likely to engage.